Absence, dysfunction or inhibition of TRPA1 has been shown to decrease inflammation- related symptoms of psoriasis [6,12,13], rheumatoid arthritis [14], actinic keratosis [15], atopic dermatitis [16,17,18], multiple sclerosis [19,20,21,22,23,24], and its function has been proposed to contribute to a variety of interrelated sensory and inflammatory processes such as inflammatory hyperalgesia [25,26], colitis [7,27], airway inflammation [28,29] and even oxidative stress storm syndromes in COVID-19 [30,31]. Here, TRPA1 is linked to atopic eczema.